Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicky Makker

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Gynecologic Oncology|January 22, 2020
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancerKaren A Cadoo, Rachel N Grisham, Roisin E O'Cearbhaill, et al.
Journal for Immunotherapy of Cancer|January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Gynecologic Oncology|January 25, 2014
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group studyGini F Fleming, Virginia L Filiaci, Brandon Marzullo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitorsRamez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
Gynecologic Oncology|May 23, 2019
Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation statusMarina Stasenko, Paulina Cybulska, Noah Feit, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Cancer|September 8, 2016
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)Vicky Makker, Fernando O Recio, Ling Ma, et al.
Gynecologic Oncology|July 11, 2024
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancerSarah Andres, Lindsey Finch, Alexia Iasonos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2023
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II TrialFunda Meric-Bernstam, Vicky Makker, Ana Oaknin, et al.
Gynecologic Oncology Reports|April 9, 2026
Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovaryMackenzie W Sullivan, M Herman Chui, Alexa N Kanbergs, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Gynecologic Oncology|January 22, 2020
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancerKaren A Cadoo, Rachel N Grisham, Roisin E O'Cearbhaill, et al.
Journal for Immunotherapy of Cancer|January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Gynecologic Oncology|January 25, 2014
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group studyGini F Fleming, Virginia L Filiaci, Brandon Marzullo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitorsRamez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
Gynecologic Oncology|May 23, 2019
Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation statusMarina Stasenko, Paulina Cybulska, Noah Feit, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Cancer|September 8, 2016
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)Vicky Makker, Fernando O Recio, Ling Ma, et al.
Gynecologic Oncology|July 11, 2024
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancerSarah Andres, Lindsey Finch, Alexia Iasonos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2023
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II TrialFunda Meric-Bernstam, Vicky Makker, Ana Oaknin, et al.
Gynecologic Oncology Reports|April 9, 2026
Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovaryMackenzie W Sullivan, M Herman Chui, Alexa N Kanbergs, et al.
Pageof 14